title: The prognostic value of the miR-200 family in ovarian cancer: a meta-analysis.
abstract: BACKGROUND
  To assess the association between miR-200 family expression and overall survival/progression-free survival in women with ovarian cancer.
  
  
  METHODS
  A systematic literature search, up to September 2015, in PubMed, EMBASE and Cochrane Library was performed to identify articles that assessed the association between miR-200 family expression and the survival of women with ovarian cancer. Summary hazard ratios and 95% confidence interval were calculated to estimate the effect.
  
  
  RESULTS
  A total of seven articles, consisting of 553 women, were included in this meta-analysis. Overall, significantly improved overall survival/progression-free survival were observed with higher expression of the miR-200 family in women with ovarian cancer (overall survival, hazard ratio = 0.34, 95% confidence interval 0.20-0.58; progression-free survival, hazard ratio = 0.64, 95% confidence interval 0.50-0.82). Subgroup analysis revealed that there was a significant association between enhanced expression of the miR-200c and improved overall survival (hazard ratio = 0.20, 95% confidence interval 0.10-0.42) and progression-free survival (hazard ratio = 0.30, 95% confidence interval 0.11-0.81). Moreover, in the Asian population, a significant association was found between higher expression of the miR-200 family and improved overall survival (hazard ratio = 0.20, 95% confidence interval 0.09-0.45).
  
  
  CONCLUSIONS
  High expression of miR-200c may predict improved survival in women with ovarian cancer and high expression of the miR-200 family significantly improves overall survival for Asian women.
authors.affiliation: Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
authors.forename: Can
authors.identifier: http://orcid.org/0000-0002-4510-6816
authors.initials: C
authors.lastname: Shi
authors.affiliation: Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
authors.forename: Zhenyu
authors.identifier: http://orcid.org/0000-0003-0377-4493
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005819:Genetic Markers; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D013489:Suppression, Genetic
chemical_list: D005819:Genetic Markers; C533896:MIRN200 microRNA, human; D035683:MicroRNAs
keywords: Meta-analysis; miR-200; ovarian cancer; survival